Discovering Innovative Solutions

for Cystic Fibrosis

Explore our efforts

Nivalis Therapeutics, Inc.

Nivalis Therapeutics (formerly N30 Pharmaceuticals) is headquartered in Boulder, Colorado. Our company is small, but passionate and growing. We have transitioned from an early-stage company solely focused on preclinical exploration, to a clinical-stage company that is focused on translating bench-side science into patient benefit.

About Us

Leading Innovation in
Cystic Fibrosis

Innovative Engineering in Cystic Fibrosis.

Learn more  

Contact Nivalis

Nivalis Therapeutics, Inc.
3122 Sterling Circle
Boulder, CO 80301
720-945-7700

Contact Us  

Latest News

  • 7
    Oct.
  • Fri, 15 Jan 16 11:16:00 -0500

    Nivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Tue, 01 Dec 15 07:00:00 -0500

    Nivalis Therapeutics Announces First Patient Dosed in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Tue, 10 Nov 15 07:00:00 -0500

    Nivalis Therapeutics to Present at the Stifel Healthcare Conference 2015

  • Download
  • 7
    Oct.
  • Mon, 02 Nov 15 16:05:00 -0500

    Nivalis Therapeutics Reports Third Quarter and Nine-Month Financial Results for 2015

  • Download
  • 7
    Oct.
  • Wed, 07 Oct 15 16:10:00 -0400

    Nivalis Therapeutics Announces Positive Phase 1b Results for N91115 in Patients With Cystic Fibrosis and Plans to Initiate Phase 2 Trial

  • Download
  • 7
    Oct.
  • Fri, 04 Sep 15 07:00:00 -0400

    Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

  • Download
  • 7
    Oct.
  • Mon, 03 Aug 15 16:10:00 -0400

    Nivalis Therapeutics Reports Financial Results for the Second Quarter 2015

  • Download
  • 7
    Oct.
  • Tue, 23 Jun 15 08:02:00 -0400

    Nivalis Therapeutics Announces Closing of Its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

  • Download
  • 7
    Oct.
  • Tue, 16 Jun 15 21:52:00 -0400

    Nivalis Therapeutics Announces Pricing of Its Initial Public Offering

  • Download
  • 7
    Oct.
  • Wed, 13 May 15 00:00:00 -0400

    Nivalis Therapeutics Files Registration Statement for Initial Public Offering of Common Stock

  • Download
  • 7
    Oct.
  • Tue, 24 Feb 15 00:00:00 -0500

    N30 Pharmaceuticals Announces Name Change to Nivalis Therapeutics

  • Download
  • 7
    Oct.
  • Tue, 03 Feb 15 00:00:00 -0500

    N30 Pharmaceuticals Appoints R. Michael Carruthers as Chief Financial Officer

  • Download
  • 7
    Oct.
  • Mon, 22 Dec 14 00:00:00 -0500

    N30 Pharmaceuticals Appoints Jon Congleton as President and CEO

  • Download
  • 7
    Oct.
  • Wed, 12 Mar 14 00:00:00 -0400

    N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy

  • Download
  • 7
    Oct.
  • Tue, 15 Oct 13 00:00:00 -0400

    N30 Pharmaceuticals Announces Presentations at the 2013 North American Cystic Fibrosis Conference

  • Download
  • 7
    Oct.
  • Tue, 02 Apr 13 00:00:00 -0400

    N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society

  • Download
  • 7
    Oct.
  • Wed, 13 Mar 13 00:00:00 -0400

    N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Mon, 08 Oct 12 00:00:00 -0400

    N30 Pharma Names Sherif Gabriel, Ph.D. as Vice President of Research

  • Download
  • 7
    Oct.
  • Tue, 21 Feb 12 00:00:00 -0500

    N30 Pharma Names Evan Loh, MD and John R. Moore to Board of Directors

  • Download
  • 7
    Oct.
  • Mon, 14 Mar 11 00:00:00 -0400

    N30 Pharmaceuticals Announces Publication of S-Nitrosoglutathione Reductase Small Molecule Inhibitor Chemistry and Development

  • Download

Leaving Nivalis.com

Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.